Skip to Main Content
Table 2.

Linear univariate and multivariate modeling of locoregional control (LRC) and overall survival (OS) probabilities as a function of clinical and biomarker covariates for the entire testing cohort

EndpointBiomarkerSpearman's rho coefficientUnivariate P valueMultivariate P value
LRC Ku80 0.487 <0.005 0.007 
 DNA-PKcs 0.305 0.006 NS 
 p16 −0.224 0.04 NS 
OS Ku80 0.465 <0.005 <0.005 
 T Stage 0.316 <0.005 NS 
 HPV −0.294 0.008 NS 
 p16 −0.284 0.01 0.02 
 DNA-PKcs 0.27 0.02 NS 
 Shh 0.267 0.02 NS 
 Rb 0.263 0.02 NS 
 BRCA1 0.252 0.03 NS 
EndpointBiomarkerSpearman's rho coefficientUnivariate P valueMultivariate P value
LRC Ku80 0.487 <0.005 0.007 
 DNA-PKcs 0.305 0.006 NS 
 p16 −0.224 0.04 NS 
OS Ku80 0.465 <0.005 <0.005 
 T Stage 0.316 <0.005 NS 
 HPV −0.294 0.008 NS 
 p16 −0.284 0.01 0.02 
 DNA-PKcs 0.27 0.02 NS 
 Shh 0.267 0.02 NS 
 Rb 0.263 0.02 NS 
 BRCA1 0.252 0.03 NS 

NOTE. Positive correlations imply a larger risk of failure for increasing expression values or stage. NS, not significant (P > 0.05). All variables listed were included in both the univariate and multivariate analyses. Other variables included in the univariate analysis that were not predictive of outcomes are not listed here; these included N stage, overall stage, radiation dose, history of tobacco use, use of chemotherapy, primary tumor location, and the remainder of the biomarkers listed in Supplementary Table S1.

Close Modal

or Create an Account

Close Modal
Close Modal